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Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the pre-
scription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies
close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin
D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the
multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin
D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria
and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus
calcimimetic centered regimens to control CKD-MBD.Thepresent review arguments these issues focusing on the opened questions
that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA
versus a calcimimetic based regimen in CKD-MBD patients.
1. Introduction
Secondary hyperparathyroidism (SHPT) is recognized as a
major complication of chronic kidney disease (CKD). Over
the past decades, Nephrologists have been encouraged to
effectively control PTHdue to the reportedworrisome conse-
quences of SHPT as brown tumors, severe cardiac hypertro-
phy, bone pain, skeletal fractures, and calciphylaxis. Although
repeated observational data described an independent associ-
ation between PTH levels and unfavorable outcomes in CKD
stage 3–5 [1–3] as well as in ESRD patients [4, 5], no random-
ized controlled trials (RCTs) have still proven that an active
reduction of PTH values could improve patient-centered out-
comes as hospitalizations, cardiovascular events (CVE), CKD
progression, and survival. Furthermore, the optimal targets of
PTH levels are still uncertain in CKD as well as in ESRD
cohorts. Thus, KDIGO guidelines provide a low-grade sug-
gestion to maintain PTH levels into the range of normality
in CKD 3–5 and between 2 and 9 times the normal range in
ESRD [6]. Active vitamin D receptor activators (VDRA) are
one of the classic therapies suggested to achieve those PTH
targets [6].
Emerging evidence of several pleiotropic effects related
to the activation of the vitamin D receptor (VDR) is trans-
forming the original world of vitamin D into a more complex
scenario and affecting the use of vitamin D sterols among
nephrologists. Different forms of vitamin D analogs are cur-
rently available in several countries, but clinical data on head
to head comparisons between them are still scanty. Nonethe-
less, promising data suggest some beneficial effects of vitamin
D analogs on proteinuria,myocardial hypertrophy in diabetic
CKD cohorts, inflammation, and cardiorenal syndromes
(Figure 1) [7, 8]. Nutritional vitamin D replenishment is also
receiving a growing interest for its potential autocrine-para-
crine effects even in CKD patients, although its use is still
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Figure 1: The growing targets of active and native vitamin D. LVH:
left ventricular hypertrophy; VC: vascular calcification; VDR: vita-
min D receptor; VDRA: vitamin D receptor activators.
based on observational rather than RCT data. Finally, the
advent of calcimimetics opened the crucial debate on the
potential benefits offered by a VDRA in respect of a calci-
mimetic based regimen against CKD-MBD and mortality in
dialysis patients.
The present reviewwill argue these issues, focusing on the
open questions that nephrologists should consider dealing
with the prescription of nutritional vitamin D or VDRA and
with the selection of a VDRA versus a calcimimetic based
regimen in CKD-MBD patients.
2. Vitamin D Metabolism in Humans and
Vitamin D Sterols Currently Available in
Nephrology Area
Humans derive vitamin D from exposure to sun light and,
into a lesser extent, from the diet. The term “nutritional vita-
min D” refers to 25(OH)D
2
and 25(OH)D
3,
the natural pre-
cursors of their active forms, 1,25(OH)
2
D
2
and 1,25(OH)
2
D
3
,
respectively, which are thereafter capable to activate theVDR.
25(OH)D
2
and 25(OH)D
3
are specifically transformed into
1,25(OH)
2
D
2
and 1,25(OH)
2
D
3
respectively by the renal and,
into a lesser extent, by the extrarenal 1 alpha hydroxylase [9].
25(OH)D
2
and 25(OH)D
3
derive from the hepatic hydrox-
ylation in the 25th position of their two precursors, ergo-
calciferol, and cholecalciferol, respectively [9]. Ergocalciferol
derives from the UV irradiation of the yeast sterol ergosterol,
naturally found in sun-exposed mushrooms, while cholecal-
ciferol fromUVB irradiation of the 7-dehydrocholesterol [10].
Notably, humans do not synthesize vitamin D2 [10]. Almost
80% of vitamin D is obtained by UVB irradiation with only a
minor contribution of diet intake [11].
Several vitamin D sterols are currently available for pre-
scription in a variety ofmedical areas (Table 1). Ergocalciferol,
cholecalciferol, and calcifediol (nutritional vitamin D) can be
currently prescribed to replenish lower levels of circulating
25(OH)D
3
. Nutritional forms of vitamin D are nowadays
flanked by several VDRA, which can activate VDR directly
or after a previous hydroxylation step. Calcitriol is the
natural VDRA [1,25(OH)
2
D
3
], capable to activate the VDR
without any prior hydroxylation process, historically adopted
to control SHPT in renal patients. More recently, four
vitamin D analogs have been introduced in the nephrol-
ogy arena, namely, alfacalcidol [1𝛼(OH)D
3
], doxercalciferol
[1𝛼(OH)D
2
] paricalcitol [19-nor1,25(OH)
2
D
3
], and oxacal-
citriol [22oxa1,25(OH)
2
D
2
]. Alfacalcidol [1𝛼(OH)D
3
] and
doxercalciferol [1𝛼(OH)D
2
] require to be hydroxylated in
25 position prior to activate the VDR, while paricalcitol
[19-nor1,25(OH)
2
D
3
] and oxacalcitriol [22oxa1,25(OH)
2
D
2
],
derived from the side chainmodification of 1,25(OH)
2
D
2
and
1,25(OH)
2
D
3
, respectively, elicit a peculiar activation of the
VDR expressed at the parathyroid gland with a lesser effect
on those expressed in the intestinal tract.
Each of these vitamin D sterols deserves specific charac-
teristics, which should be taken into account by nephrologists
while approaching any vitamin D regimen.
3. Nutritional Vitamin D: Protective
Replenishment or Active Therapy?
Nutritional vitamin D has received an exponential interest of
scientific press during the last ten years.Themedical literature
yearly hosts tenths of papers describing associations between
circulating levels of 25(OH)D and a variety of diseases, from
osteoporosis [12] to hypertension [13], cardiovascular disease
[14], insulin resistance [15], infections [16], cancer [17] and
mortality [18]. 25(OH)D deficiency has been similarly linked
to CKD progression [19], SHPT [20], and survival [21] in
renal patients.Thewidespread association between 25(OH)D
and unfavorable outcomes in the general population, as well
as in selected diseased subcohorts, inspired a potential role
of nutritional vitamin D as an etiologic factor rather than a
mere biomarker of clinical debacles.The emerging knowledge
about the extrarenal activation of 25(OH)D, prompting the
calcitriol-related genomic effects at an autocrine and para-
crine level, extended the hypothesis of such a causal link also
in CKD cohorts [22]. Nutritional vitamin D (cholecalciferol,
ergocalciferol, or calcifediol) is nowadays prescribed when
25(OH)D levels fall under 30 ng/mL in the community as well
as in CKD and ESRD patients. However, the desirable targets
of 25(OH)D are still prone to current revaluations [12, 23, 24].
KDIGO guidelines provide a not graded suggestion to replen-
ish 25(OH)D deficiency as the first step to correct SHPT in
CKD stage 3–5 [6], while no suggestions are provided on the
administration of nutritional vitamin D in dialysis patients.
Although these relevant associations, crucial aspects still
require attention prior to trace enthusiastic conclusions about
the effect of nutritional vitamin D replenishment on patient-
centered outcomes in CKD-ESRD patients.
Levels of 25(OH)D > 30 ng/mL are considered sufficient,
levels of 21 to 29 ng/are defined as insufficient, while levels
below 20 ng/mL are considered deficient [9]. 25(OH)D defi-
ciency is highly prevalent in the general population as well as
in CKD, exceeding 80% in dialysis patients [25]. Physicians
can actually replenish 25(OH)D deficiency with the 3 nutri-
tional drugs: ergocalciferol, cholecalciferol, and calcifediol.
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Table 1: Vitamin D sterols currently available as medical treatments in nephrology field.
Nutritional vitamin D VDRA
Hydroxylation required to
activate VDR
Hydroxylation
required to activate
VDR
Vitamin D2
and its analogs Ergocalciferol
25-hydroxylation and
1-hydroxylation
Paricalcitol
19-nor1,25(OH)2D3
—
Doxercalciferol 1a(OH)D2 25-hydroxylation
Vitamin D3
and its analogs
Calcitriol
1,25(OH)2D3
—
Cholecalciferol 25-hydroxylation and1-hydroxylation Alfacalcidol 1a(OH)D3 25-hydroxylation
Calcifediol 1-hydroxylation Oxacalcitriol22oxa1,25(OH)2D2
—
Note: all the VDRA reported in the table are considered analogs with the only exception of calcitriol, which corresponds to the natural form of 1,25(OH)2D3.
LVDRA: vitamin D receptor activators; VDR: vitamin D receptor.
Several studies observed that ergocalciferol was less potent
than cholecalciferol in achieving 25(OH)D targets [26]. This
could be due to a stronger affinity of cholecalciferol to the
vitamin D binding protein [27]. Furthermore, the activation
of vitamin D receptor (VDR) by 1-25(OH)
2
D
3
could be more
sustained due to the capability of 1-24-25(OH)
3
D
3
to still
activate VDR [27], contrarily to what is observed for 1-24-
25(OH)
3
D
2
[28]. Thus, 50.000 IU of ergocalciferol are pur-
posed as equivalent to 15.000–5.000 IUof cholecalciferol [29].
Notably, in a recent post hoc analysis by Biancuzzo et al. of a
previously published double-blind placebo-controlled trial,
ergocalciferol 1000UI/day for 11 weeks was equivalent to
cholecalciferol at the same dose in improving the circulating
levels of 25(OH)D [30]. Two registered RCTs are actually
recruiting patients to compare the effect of vitamin D2
against vitamin D3 onmineral metabolism in CKD stage 2–5
(NCT01633853, NCT01173848). Notably, the choice of the
“prodrugs” ergocalciferol or cholecalciferol, compared to cal-
cifediol, could be more protective against the risk of further
calcitriol intoxication. Particular attention is always manda-
tory while prescribing nutritional vitamin D in the cases of
suspected 1-alpha-hydroxylase overexpression, as it is for sar-
coidosis or B-cell lymphomas. Nigwekar et al. have recently
proposed an 8 to 16 weeks regimen to replenish 25(OH)D
deficiency in CKD patients, starting with 50.000 IU ergocal-
ciferol or 10.000 IU cholecalciferol weekly [29].
Nutritional Vitamin D can be activated also in renal
patients by the extrarenal 1-alpha-hydroxylase, mainly
expressed in monocytes/macrophages and parathyroid cells
[22]. According to the recent meta-analysis by Kandula and
colleagues, observational studies demonstrate that nutri-
tional vitamin D reduces PTH levels in CKD (−24.24 pg/mL)
as well as in ESRD (−59.49 pg/mL) patients [31]. However,
the studies were heterogeneous for the nutritional vitamin D
prescription in terms of type, doses, and route of administra-
tion [31]. More recently Alvarez and colleagues randomized
48 CKD 2-3 patients to cholecalciferol versus placebo [32].
Cholecalciferol improved SHPT compared to placebo up
to one year of followup [32]. The entity of PTH reduction
suggests a significant impact of nutritional vitamin D admin-
istration only for mild SHPT, being limited to an adjuvant
role in the majority of other cases.The early replenishment of
nutritional vitamin D deficiency could rather be preventive,
delaying the further onset and evolution of SHPT [33]. Obser-
vational data from Tassin showed a progressive reduction of
PTH levels in incident dialysis patients since 2004 to 2009,
parallel to the increased prevalence of cholecalciferol and
calcifediol prescription in the same incident individuals [34].
VDRA are expected to elicit a stronger PTH reduction
compared to their native forms. The Cochrane meta-analysis
by Palmer et al. reported a 196.05 pg/mL reduction of PTH
levels in dialysis patients, receiving VDRA [35], which was
three times higher than that reported for nutritional vitamin
D [31]. Paricalcitol and doxercalciferol induced a stronger
PTH reduction compared to ergocalciferol and cholecalcif-
erol in CKD 3-4 patients respectively [36, 37]. However, the
comparison between nutritional vitamin D and VDRAs in
achieving the suggested PTH targets needs to be deepened in
further RCTs.
Data concerning PTH reduction by the coadministration
of nutritional vitamin D and VDRA are still heterogeneous
and mainly acquired in observational fashion [38]. Further-
more, only a subset of patients concomitantly received the
nutritional and the active vitaminD in those studies [39]. Cal-
cifediol was associatedwith a significant PTH reduction and a
lowering rate of alfacalcidol administration from 66% to 43%
in 149 dialysis patients during 6 months of followup [40].
Contrarily, cholecalciferol 20.000 IU/week did not impact on
PTH reduction in 64 dialysis patients, 40 of whom were
undergoing calcitriol or alfacalcidol [41]. PTH remained
similarly unchanged in 42 dialysis patients on VDRA ran-
domized to nutritional vitamin D (10.333 IU cholecalcif-
erol/week) versus placebo [42]. Matias et al. investigated 158
dialysis patients (44% receiving paricalcitol) treated with one
year cholecalciferol administration at doses tailored to basal
25(OH)D levels, with amaximumof 50.000 IU per week [43].
A significant mild decrease in iPTH levels (from 233 to
208 pg/mL, 𝑃 < 0.001) was accompanied by a mild reduction
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Table 2: Burning questions on vitamin D prescription in CKD-MBD.
VDRA Nutritional vitamin D VDRA or calcimimetic
(i) Are VDRA superior to placebo in terms of
cardiovascular events and survival?
(ii) Do vitamin D analogs provide a better
achievement of patient centered outcomes
compared to calcitriol?
(iii) Is any VDRA superior to the others in
achieving KDIGO targets and improving
albuminuria, LVH, VC, bone health,
hospitalizations, and survival?
(iv) Will paricalcitol ameliorate CKD
progression and cardiovascular events through
the benefits on albuminuria and LVH?
(v) Should VDRA be suspended in those
patients reaching PTH levels ≤ 150 pg/mL?
(i) Which are the optimal thresholds
independently linked to SHPT and survival?
(ii) Which is the best nutritional vitamin D
regimen in terms of type and doses to replenish
deficiency and treat SHPT?
(iii) Will the replenishment be a cost-effective
prevention against SHPT and CKD-MBD?
(iv) Will the replenishment improve CKD
progression, diabetes, infections, and survival?
(v) Will the coadministration of native and
active vitamin D be additive against
CKD-MBD, infections, diabetes, and
mortality?
(i) Is a VDRA-centered superior to a
calcimimetic-centered therapy to
control SHPT and survival?
(ii) Which is the best cost-effective
strategy in CKD-MBD: VDRA alone,
calcimimetic alone, or a balanced
association of VDRA and
calcimimetic?
CKD: chronic kidney disease; SHPT: secondary hyperparathyroidism; LVH: left ventricular hypertrophy; VC: vascular calcification; VDRA: vitaminD receptor
activators.
in the doses of paricalcitol [43]. Finally, a short run with
very high doses of cholecalciferol (200.000/week for 3 weeks)
resulted similar to placebo in terms of PTH reduction at 6
weeks despite the increase of 25(OH)D up to 52.4±18 ng/mL
[44]. Of note, some studies observed a mild, but significant,
increase of calcium levels during nutritional vitamin D
administration [40, 41, 45]. More recently, Delanaye et al.
observed a significant difference in the 12months PTH reduc-
tion among 43 hemodialysis patients randomized to cholecal-
ciferol 25.000UI every two weeks [−115 pg/mL (95% CI: −192
to 81)] versus placebo [+80 pg/mL (95% CI: −58 to 153)] (𝑃 =
0.02) [46].
The effect of nutritional vitamin D on bone histology of
renal patients has been poorly investigated. Coen et al. retro-
spectively observed a reduction in bone turnover of dialysis
patients with 25(OH)D levels higher than 40 ng/mL [47].
Specific RCTs are advocated to test this relevant issue.
VDRAs consistently increase FGF23 levels [48–50] in
predialysis patients. Nutritional vitamin D seems to elicit a
similar effect, which could be however different according to
the type and the regimen of vitamin D adopted [32, 51]. The
clinical relevance of FGF23 variations induced by vitaminD is
an intricate topic beyond the purposes of this review.
Great expectations are placed in the possible pleiotropic
effects of nutritional vitamin D. The synthesis of extrarenal
1-alpha hydroxylase in multiple cell lines and the ubiquitous
expression of VDR suggest that the 25(OH)D provision could
sustain its activation, favoring the VDR-mediated genomic
effect of calcitriol at an autocrine and paracrine level [22].
Kim et al. observed a 25% reduction of urinary albumin-to-
creatinine ratio (UACR) in CKD diabetic patients random-
ized to cholecalciferol against placebo on top of ACE-I
or ARBs [52]. Cholecalciferol administered at high doses
was heterogeneously associated with improved left ven-
tricular hypertrophy [45], erythropoietin doses [43], endo-
toxin activity [53], and inflammation [45, 54]. Several RCTs
are currently investigating the potential effect of nutri-
tional vitamin D on LVH (NCT01323712), insulin resistance
(NCT00893451), erythropoietin dosing (NCT01395823), pro-
teinuria (NCT01426724) immunity (NCT00892099), arter-
ovenous fistulae maturation (NCT00912782), and physical
and cognitive performance (NCT00511225, NCT01229878).
A recent meta-analysis described a 14% increased mor-
tality risk for each 10 ng/mL reduction of 25(OH)D levels in
CKD cohorts [21]. Although vitaminD replenishment is gen-
erally adopted at levels inferior to 30 ng/mL in renal patients,
certain studies showed an increased risk of ESRD [19] and
mortality [55] at lower 25(OH)D levels. Though the associa-
tion between 25(OH)D levels andmortality was attenuated in
dialysis patients receiving VDRA [55], no RCTs have inves-
tigated the effect of nutritional vitamin D supplementation
on survival in renal ESRD cohorts.The NUTRIVITA study is
randomizing Italian dialysis patients to calcifediol versus con-
trol to test the effect of treatment on survival, nonfatal myo-
cardial infarction, and stroke (NCT01457001).
While awaiting for new evidences, the not gradedKDIGO
suggestion to supplement nutritional vitamin D to achieve
levels of 25(OH)D of at least 30 ng/mL seems acceptable as a
complementary step in SHPT management, especially in the
early stages of CKD. However, the following burning ques-
tions still deserve to be answered by dedicatedRCTs (Table 2):
(1) What are the optimal levels of 25(OH)D to aim for to
ameliorate both SHPT control and survival in renal
patients?
(2) What is the best nutritional vitamin D type (chole-
calciferol, ergocalciferol, or calcifediol) and dose reg-
imen to correct 25(OH)D deficiency and treat SHPT?
(3) Is the correction of 25(OH)D deficiency in the earlier
stages of CKD cost-effective to prevent CKD-MBD?
(4) Does nutritional vitaminD supplementation improve
CKDprogression, diabetes, infections, and survival in
renal patients?
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(5) Is the coadministration of nutritional vitamin D and
VDRA associated with additive benefits on CKD-
MBD, infections, and diabetes control as well as mor-
tality in CKD patients?
4. VDRA: A Multifaceted Choice from
Secondary Hyperparathyroidism to Survival
The reduction of serum 1,25(OH)
2
D and calcium levels
together with total body phosphate expansion are the major
causes of SHPT. Hence, VDRA are traditionally considered
a cardinal treatment of SHPT. KDIGO guidelines suggest
starting a VDRA in case of raising PTH values in the course
of CKD [6]. On the contrary, its suspension or reduction is
suggested in the case of hypercalcemia or hyperphosphatemia
[6]. The risks related to high doses of vitamin D are mainly
due to phosphate and calcium overload which are both
associated with worse survival in dialysis patients [56, 57].
Furthermore, the achievement of the suggested calcium and
phosphate targets is still suboptimal in the European dialysis
population, as reported by the recent COSMOS investigation
[58].Thus, selective VDRAwith a stronger effect on PTH and
a lesser impact on calcium and phosphate load may improve
the global achievement of mineral targets reducing the toxic-
ity of high vitamin D dosage.
In the recent years, industries have providedmultiple syn-
thetic vitamin D, namely, vitamin D2 (paricalcitol and doxer-
calciferol) and vitaminD3 analogs (alfacalcidol, falecalcitriol,
and oxacalcitriol) (Table 1).Thesemolecules actually received
a growing interest for their capability to control PTH values
with a lower impact on phosphate and calcium levels com-
pared to calcitriol [59–61] in some instances reported similar
to placebo [62–64]. However, many questions are still opened
about the comparison between different vitamin D analogs
on mineral metabolism, surrogate endpoints, and patient-
centered outcomes.
Although an encouraging superiority of single analogs
against placebo and calcitriol in controlling PTH, calcium,
and phosphate, only few studies compared the impact of
different analogs on serumCKD-MBD targets, leading to het-
erogeneous and inconclusive results. Alfacalcidol was similar
to calcitriol in suppressing PTH values with equal change
in phosphate and calcium levels [65, 66], but recent data
by Hansen et al. did not observe any significant difference
between alfacalcidol and paricalcitol on similar targets [67].
Joist et al. observed that paricalcitol at very high doses, far
from those commonly adopted in clinical practice, sup-
pressed PTH with lower elevation of phosphate and calcium
levels compared to doxercalciferol [68], but the conversion
from intravenous paricalcitol to doxercalciferol resulted in
equally satisfactory control of PTH, calcium and phosphate
[69]. No clinical data comparing doxercalciferol with alfacal-
cidol in humans are currently available.
Different vitaminD analogsmay induce a peculiar activa-
tion of VDR with substantial different effects on the vascular
calcification (VC) and bone remodeling pathways. Experi-
mental data observed that VC and arterial stiffness were less
pronounced in rats treated with paricalcitol, compared to
those receiving other VDRAs [70–72]. Paricalcitol resulted
also bone protective in experimental models compared to
vehicle [73] and with a lower risk of adynamic bone disease
compared to calcitriol [74], doxercalciferol [75], or cinacalcet
[38]. However, the expected effect of different vitamin D
analogs on bone and vascular health are still unexplored in
humans.
More recently nutritional vitamin D and VDRA received
growing interest for their potential pleiotropic effects, related
to the widespread regulation of human genome played by
VDR activation. Albuminuria and left ventricular hypertro-
phy (LVH) of diabetic CKD patients emerged as new targets
of vitaminD analogs [76].The activation of VDR can actually
regulate the expression of several genes involved in glomeru-
lar and myocardial inflammation as renin [77], TGF-beta
[78], antioxidant molecules [79], NF𝜅B, and RANTES [80].
The VITAL study, a randomized placebo controlled trial in
diabetic CKD patients, confirmed a significant, dose depen-
dent and reversible reduction of albuminuria when paricalci-
tol was added to RAAS inhibitors [81]. More recently a post
hoc analysis of the PRIMO study observed a lower increase
of brain natriuretic peptide and left atrial index in diabetic
CKD patients receiving paricalcitol on top of ACE-I or ARBs
compared to placebo [82]. Interestingly, paricalcitol was asso-
ciated with lower risk of hospitalization in those patients with
more severe LVH [83]. Of note, paricalcitol resulted associ-
ated with significant reduction of oxidative stress [84] and
improved peritonealmembrane permeability in hemodialysis
and peritoneal dialysis, respectively [85]. However, no RCTs
have tested the effect of paricalcitol against other forms of
vitamin D on albuminuria and LVH. Furthermore, no RCTs
have investigated if the benefits offered by paricalcitol against
placebo on albuminuria and LVHmay improve hard patient-
centered outcomes.
The aforementioned data suggested potential benefits
offered by vitaminD analogs on hospitalization, cardiovascu-
lar events, and mortality. Several observational data support
these hypotheses. A 14% reduction in all-cause hospitaliza-
tion was observed in hemodialysis patients receiving parical-
citol compared to those treated with calcitriol [5]. Paricalcitol
[86–88] and doxercalciferol [86] resulted associated with
lower mortality compared to calcitriol. However, in the
DOPPS cohort VDRA administration was not associated
with improved survival in models more independent of
unmeasured confounders as comorbidities [89]. Results from
the Italian FARO survey unexpectedly showed a better sur-
vival in dialysis patients receiving VDRA also in the presence
of PTH ≤ 150 pg/mL [90]. The evidence-based approach
requires further RCTs to confirm these observational data
prior to orient stronger recommendations on VDRA pre-
scription. However, while the head to head comparison
between different VDRA would be ethically acceptable, the
direct comparison between VDRA versus placebo in the
absence of other treatments against SHPT as calcimimetics
would be ethically questionable for the reason mentioned
previously. This ethical conundrum still entraps the birth of
newRCTs to support higher grade recommendations on vita-
min D prescriptions.
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The adoption of VDRA appears heterogeneous across
Europe. Recent data from the COSMOS study presented a
limited use of VDRA in European dialysis patients (48%),
with calcitriol and alfacalcidol accounting for 93.3% and pari-
calcitol for 6.7% [58].The adoption of alfacalcidol was double
that of calcitriol in the non-Mediterranean countries, and the
opposite was seen inMediterranean areas [58]. Data form the
Italian FARO survey describe an increase in the prescription
of iv paricalcitol from 24.4% to 41.9% and a consensual reduc-
tion in the prescription of calcitriol since April 2006 to Octo-
ber 2007, among dialysis patients with iPTH > 150 pg/mL
[90]. Similar trends are reported by the United Renal Data
System between 1999 and 2008, with a declined use of
intravenous calcitriol from 83.9% to 1.8%, accompanied by a
raise in paricalcitol and doxercalciferol intravenous adoption
[91].Health-economic analysis observed that paricalcitolmay
have potential economic benefits in both CKD and dialysis
patients compared to calcitriol and alfacalcidol [92, 93].
Furthermore, a recent economic analysis of the FARO sur-
vey observed that intravenous paricalcitol was more cost-
effetctive compared to the combination of paricalcitol plus
cinacalcet [94]. However, any economic consideration is
far from being conclusive, coming from observational data
rather than from controlled intervention.
In the authors opinion, this body of insights raises the
following questions, which still deserve to be investigated in
further RCTs (Table 2):
(1) Is any VDRA superior to placebo in terms of cardio-
vascular events and survival?
(2) Do vitamin analogs provide a better achievement of
patient centered outcomes compared to calcitriol?
(3) Is any vitamin D analog superior to the others in
achieving KDIGO targets and improving albumin-
uria, LVH, VC, CVE, bone health, hospitalizations,
and survival?
(4) Will paricalcitol ameliorateCKDprogression and car-
diovascular events through the benefits on albumin-
uria and LVH?
(5) Should VDRA be suspended in those patients reach-
ing PTH levels ≤ 150 pg/mL?
5. VDRA and/or Calcimimetic:
The Open Debate
Differences between a VDRA versus a calcimimetic-centered
regimen represent an open debate in the management CKD-
MBD in dialysis patients [95]. The main terms of this com-
parison are focused on SHPT control, progression of VC, and
survival.
Two recent RCTs, the ACHIEVE [96] and the IMPACT
[97] study, investigated the effect of these regimens against
SHPT, leading to conflicting results. The SHPT control
resulted superior in the cinacalcet and in the paricalcitol
iv centered group in the ACHIEVE and the IMPACT trial
respectively. Notably, somemajor differences in the two study
designs may account for these discrepant results: (1) in the
ACHIEVE study the active VDRA group included both
paricalcitol and doxercalciferol, while paricalcitol was the
only VDRA accepted in the D arm of the IMPACT study, (2)
cinacalcet was admitted for hypercalcemia during VDRA in
the IMPACT study, while it was excluded from the D arm in
theACHIEVE study, and (3) the laboratory parameter thresh-
olds selected to introduce or suspend cincalacet and VDRA
were different in the two trials. On the opposite, both the
studies presented higher rates of hypocalcemia and increas-
ing adoption of calcium-based phosphate binders in the
cincalacet arm. In light of the study design differences, these
results do not allow absolute conclusions about the potential
superiority of any of these two approaches against SHPT.
The recently published ADVANCE trial [98] investigated
whether cinacalcet in combination with low dose of VDRA
(<6mcg paricalcitol equivalent/week) versus flexible doses
of VDRA attenuates coronary, aorta, and cardiac valves
calcification progression in 360 hemodialysis patients. After
12 months of followup, a trend toward CAC reduction in the
cinacalcet arm was noted [24% (95% CI: −22% to 119%)] and
[31% (95% CI: −9% to 179%)], in the cinacalcet and flexible
vitamin D group, respectively (𝑃 = 0.073). Of interest, as
in the ACHIEVE study, in the ADVANCE study protocol no
specific recommendation on vitamin D administration was
made resulting in an heterogeneous use of different forms of
VDRA. Finally, the large dose of calcium containing phos-
phate binders and vitamin D administered in the calcimi-
metic arm further complicate the interpretation of these
results [99].
The effect on hard endpoints offered by cinacalcet versus
placebo, on top of traditional therapies against SHPT (VDRA
and phosphate binders), was recently investigated by the
EVOLVE trial [100]. As in the ACHIEVE and ADVANCE
study, VDRA therapywas not controlled by the EVOLVEpro-
tocol, with the exception of VDRA adjustments in the case of
iPTH < 150 pg/mL or hypocalcemia. Thus, the EVOLVE trial
was not designed to assess a head to head VDRA and cinacal-
cet but rather the impact of cinacalcet on survival in addition
to the more heterogeneous ongoing treatments of SHPT. At
study end, a statistically nonsignificant trend toward reduc-
tion of the composite endpoint (time to death, myocardial
infarction, hospitalization for unstable angina, heart failure,
or a peripheral vascular event) was reported [relative hazard
in the cinacalcet versus the placebo group 0.93 (95% CI: 0.85
to 1.02), 𝑃 = 0.11)] [99]. However, the lower the anticipated
event rate, the higher drop-in and -out rate during followup
(about 20%) significantly affected the statistical power (0.54)
and the interpretability of this inconclusive RCT [100].
Increasing the dose of cinacalcet or VDRA could be
similarly effective on PTH suppression, with different effects
on calcium-phosphate metabolism consequent to the VDR
versus the calcium sensing receptor activation. Furthermore,
the peculiar effects of each VDRA encourages further RCTs
to test cinacalcet against a particular VDRA rather than a het-
erogeneous VDRA menu. Although the promising results of
theADVANCEand the EVOLVE trials, any superiority of cal-
cimimetics versus vitaminD, or vice versa, onVCprogression
and hard end points is far from being established.
BioMed Research International 7
6. Conclusions
An expanding body of evidence is rapidly enriching the ratio-
nale for vitamin D use in CKD-MBD. The traditional action
of VDRAs on PTH suppression is now flanked by encour-
aging data on their pleiotropic effects on microalbuminuria
and LVH. Furthermore, nutritional Vitamin D is receiving
a growing interest as a preventive and treating strategy
against SHPT as well as a protective intervention on immune
responses, insulin resistance, and inflammation even in renal
patients. However, further RCTs are advocated to investigates
themany opened questions and uncertainties on the effects of
VDRA and nutritional vitamin D on hard end points and
their comparison with calcimimetic in CKD.
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